tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ALT Stock Latest News

Altimmune’s Earnings Call Highlights NASH Trial Success and Financial Strength
Company AnnouncementsAltimmune’s Earnings Call Highlights NASH Trial Success and Financial Strength
5d ago
ALT
Altimmune rallies after FDA accepts liver stiffness as MASH endpoint
PremiumThe Fly
Altimmune rallies after FDA accepts liver stiffness as MASH endpoint
10d ago
ALT
Altimmune announces FDA Fast Track designation for pemvidutide
PremiumThe Fly
Altimmune announces FDA Fast Track designation for pemvidutide
18d ago
ALT
Altimmune price target lowered to $24 from $26 at UBS
PremiumThe Fly
Altimmune price target lowered to $24 from $26 at UBS
24d ago
ALT
Altimmune’s Pemvidutide Advances Towards Phase 3 Trials with Promising Data and Strategic Leadership
PremiumRatings
Altimmune’s Pemvidutide Advances Towards Phase 3 Trials with Promising Data and Strategic Leadership
24d ago
ALT
Altimmune Reports Promising Trial Results and Financial Growth
PremiumCompany AnnouncementsAltimmune Reports Promising Trial Results and Financial Growth
24d ago
ALT
Altimmune’s Pemvidutide Faces Uncertainty Amid MASH Market Challenges and Pending Developments
Premium
Ratings
Altimmune’s Pemvidutide Faces Uncertainty Amid MASH Market Challenges and Pending Developments
25d ago
ALT
Altimmune reports Q2 EPS (27c), consensus (32c)
Premium
The Fly
Altimmune reports Q2 EPS (27c), consensus (32c)
25d ago
ALT
Options Volatility and Implied Earnings Moves Today, August 12, 2025
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, August 12, 2025
25d ago
SE
ALT
Altimmune board of directors appoint Jerry Durso as Chairman
PremiumThe Fly
Altimmune board of directors appoint Jerry Durso as Chairman
26d ago
ALT
Options Volatility and Implied Earnings Moves This Week, August 11 – August 14, 2025
PremiumMarket News
Options Volatility and Implied Earnings Moves This Week, August 11 – August 14, 2025
26d ago
DE
JD
Altimmune Faces Legal Storm as Trial Results Disappoint
PremiumClass Action
Altimmune Faces Legal Storm as Trial Results Disappoint
1M ago
ALT
ALT Earnings this Week: How Will it Perform?
PremiumPre-EarningsALT Earnings this Week: How Will it Perform?
1M ago
ALT
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
2M ago
NB
ALT
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
Premium
Company Announcements
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
2M ago
ALT
Altimmune price target lowered to $15 from $25 at Citizens JMP
PremiumThe Fly
Altimmune price target lowered to $15 from $25 at Citizens JMP
2M ago
ALT
Altimmune resumed with a Sell at Goldman Sachs
PremiumThe Fly
Altimmune resumed with a Sell at Goldman Sachs
2M ago
ALT
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development
PremiumRatings
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development
2M ago
ALT
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
PremiumCompany Announcements
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
2M ago
ALT
Altimmune enrolls first patient in Restore Phase 2 trial
PremiumThe FlyAltimmune enrolls first patient in Restore Phase 2 trial
2M ago
ALT
Altimmune’s Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential
Premium
Ratings
Altimmune’s Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential
2M ago
ALT
Optimistic Outlook for Altimmune’s Pemvidutide Despite Phase 2b Setback
Premium
Ratings
Optimistic Outlook for Altimmune’s Pemvidutide Despite Phase 2b Setback
2M ago
ALT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >